News Feature
Nature Biotechnology 25, 1379 - 1381 (2007)
doi:10.1038/nbt1207-1379
Hepatitis C: staying the course
Ken Garber1
- Ann Arbor, Michigan
Abstract
A rash of failures for hepatitis C drugs, conflicting theories about the immune system's role and the looming issue of drug resistance make it impossible to predict when or how new therapies will make an impact. Ken Garber reports.
